Polynoma

What Polynoma does

Polynoma is a clinical-stage biotechnology company founded in 2007 and headquartered in San Diego, California, historically focused on cancer vaccine research and development for the treatment of melanoma. Its principal therapeutic asset, Seviprotimut-L, is a melanoma vaccine candidate designed to stimulate an immune response against melanoma-associated antigens. The company historically operated with a small team of 11 to 50 employees and had no commercial products, disclosed pricing models, or enterprise customers prior to the corporate events of late 2025.

In October 2025, Polynoma's corporate structure changed materially. DEFJ, LLC, the prior parent of Polynoma, LLC, sold Polynoma, LLC to TransCode Therapeutics in exchange for Series A Preferred Stock plus up to $95 million in potential milestone payments, concurrent with a $25 million equity investment from DEFJ. In a related transaction, CK Life Sciences International merged its subsidiary Polynoma with publicly listed TransCode Therapeutics (NASDAQ: RNAZ), issuing approximately $125 million in shares and gaining a controlling stake in the combined entity. As a result, Polynoma, LLC is now a wholly-owned subsidiary within TransCode's broader immuno-oncology and RNA therapeutics platform.

Post-merger, Polynoma's Seviprotimut-L asset is being evaluated for combination synergies with TransCode's lead candidate TTX-MC138 — an RNA-based therapeutic targeting microRNA-10b in metastatic cancers — through a sponsored research agreement with Michigan State University signed in April 2026. The company generates no commercial product revenue; future revenue is expected to come from licensing agreements, milestone payments, and eventual product sales upon regulatory approval, none of which are currently disclosed. Distribution is currently limited to clinical trial sites, with no commercial pharmaceutical supply chain in place.

Name

Polynoma

Legal name

TransCode Therapeutics, Inc.

Website

https://polynoma.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Polynoma is a clinical-stage biotechnology company founded in 2007 in San Diego, focused on cancer vaccine R&D for melanoma. Its lead asset Seviprotimut-L was acquired by TransCode Therapeutics in October 2025 as part of a CK Life Sciences-backed merger.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics — Melanoma Vaccine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• Cancer vaccine development
• Melanoma immunotherapy
• Oncology therapeutics
• Biopharmaceutical research
• Clinical stage biotechnology

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage company developing RNA-based cancer therapeutics. Revenue generation will come from future product sales upon regulatory approval and commercialization of therapeutic candidates in the pipeline.
2. Licensing and milestone payments: Acquired Seviprotimut-L through prior acquisition of Polynoma, LLC's parent company. Future revenue may come from licensing agreements, milestone payments from pharmaceutical partnerships, and potential co-development arrangements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Polynoma is a biotechnology firm developing cancer vaccines for the treatment of melanoma, with its principal asset Seviprotimut-L as a therapeutic vaccine candidate. The company was acquired by TransCode Therapeutics in October 2025, integrating Seviprotimut-L into a broader immuno-oncology pipeline that is exploring combination use with the lead candidate TTX-MC138.

Product overview

Polynoma is a biotech company focused on RNA-based immuno-oncology therapeutics for treating high-risk and advanced metastatic cancers. Its core product is TTX-MC138, a microRNA-10b inhibitor delivered via the proprietary TTX iron oxide nanoparticle platform. The company expanded its pipeline through the acquisition of Polynoma LLC (adding Seviprotimut-L) and a licensing agreement with Unleash Immuno Oncolytics for an oncolytic immunotherapy platform targeting bladder cancer. The TTX platform enables delivery of synthetic RNA oligonucleotides to cancer cells, addressing a decades-long challenge in the field.

Differentiator

Problem solved

Functional benefit

Brands

• TTX: Iron oxide nanoparticle delivery platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics, designed to deliver oligonucleotides (synthetic RNA) to cancer cells with high tunability.

Products and services

• Seviprotimut-L

Quantifiable outcome

• Durable regression of established metastases in pre-clinical murine models of metastatic breast cancer and pancreatic cancer without recurrence
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Michigan State UniversitycoreStrategic or Co-development Partner · 27 April 2026Sponsored research agreement with Michigan State University to accelerate development of pipeline candidates, including evaluation of lead therapeutic TTX-MC138 in combination with Seviprotimut-L for potential synergies. Dr. Anna Moore, the globally recognized expert joining as SAB Chair, will provide strategic guidance.
• Unleash Immuno Oncolytics, Inc.coreStrategic or Co-development Partner · 1 March 2026Exclusive licensing agreement for a preclinical oncolytic immunotherapy platform targeting muscle-invasive bladder cancer, expanding the oncology pipeline.
• DEFJ, LLC (former parent of Polynoma)minorStrategic or Co-development Partner · 1 October 2025DEFJ, LLC sold Polynoma, LLC (parent of ABCJ, LLC) to TransCode for Series A Preferred Stock plus up to $95 million in milestone payments. DEFJ also made a concurrent $25 million investment in TransCode.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/polynoma

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polynoma